Production (Stage)
Interpace Biosciences, Inc.
IDXG
$0.80
$0.022.56%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.27% | 16.98% | 16.62% | 10.78% | 19.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.27% | 16.98% | 16.62% | 10.78% | 19.69% |
| Cost of Revenue | 12.97% | 11.26% | 3.87% | 4.06% | 5.69% |
| Gross Profit | 22.99% | 20.40% | 25.28% | 15.20% | 29.86% |
| SG&A Expenses | 8.21% | 7.90% | 3.58% | -2.35% | -0.15% |
| Depreciation & Amortization | -- | -- | -97.66% | -82.22% | -57.17% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.67% | 6.68% | 0.66% | -2.54% | 0.15% |
| Operating Income | 105.88% | 110.65% | 374.46% | 570.54% | 301.19% |
| Income Before Tax | 205.90% | 215.21% | 675.85% | 340.13% | 162.16% |
| Income Tax Expenses | 5.88% | -76.47% | 0.00% | 750.00% | 21.43% |
| Earnings from Continuing Operations | 207.18% | 217.40% | 665.50% | 338.94% | 161.56% |
| Earnings from Discontinued Operations | 26.27% | 21.29% | 65.87% | 98.59% | 97.78% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 241.02% | 255.27% | 468.77% | 127.54% | 111.94% |
| EBIT | 105.88% | 110.65% | 374.46% | 570.54% | 301.19% |
| EBITDA | 83.57% | 73.34% | 172.87% | 143.31% | 9,767.92% |
| EPS Basic | 217.04% | 226.92% | 461.38% | 126.78% | 111.65% |
| Normalized Basic EPS | 201.17% | 209.59% | 712.42% | 345.06% | 157.79% |
| EPS Diluted | 64.06% | 117.16% | 458.88% | 126.69% | 111.56% |
| Normalized Diluted EPS | 49.47% | 96.73% | 709.78% | 344.05% | 157.66% |
| Average Basic Shares Outstanding | 1.53% | 1.61% | 1.53% | 1.55% | 1.66% |
| Average Diluted Shares Outstanding | 396.87% | 264.13% | 1.94% | 1.79% | 1.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |